Arcutis Biotherapeutics ARQT 深 沪
已收盘 12-19 16:00:00 美东时间
28.01
+0.230
+0.83%
华盛通- 最 高28.66
- 今 开27.995
- 成交量 398.19万股
- 最 低 27.822
- 昨 收 27.78
- 总市值 33.61亿
- 52周最高 31.77
- 市盈率 静 --
- 换手率 3.32%
- 52周最低 11.13
- 委 比 63.64%
- 总股本 1.20亿
- 历史最高 40.88
- 量 比 1.78
- 振 幅 3.02%
- 历史最低 1.76
- 每 手 1
- 风险率 4.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis Biotherapeutics Appoints Amit Munshi as New Director
Arcutis Biotherapeutics ( ($ARQT) ) has provided an update. On December 3, 2025...
12-09 05:44
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $37
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and raises the price target from $32 to $37.
11-28 23:11
Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis
The U.S. FDA has accepted a sNDA from Arcutis Biotherapeutics (ARQT) for its Zoryve (roflumilast) cream for the treatment of plaque psoriasis in children ages two to five years old. The application ha...
11-17 22:05
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest
Arcutis Biotherapeutics Inc's (NYSE:ARQT) short interest as a percent of float ...
11-14 03:00
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics has expanded its rare disease pipeline, with four QTORIN™-derived candidates targeting serious, rare skin diseases without FDA-approved therapies. Top-line results for the Phase 2 TOIVA trial (QTORIN™ rapamycin for cutaneous venous malformations) are expected mid-December 2025, while Phase 3 SELVA trial results (microcystic lymphatic malformations) are anticipated in Q1 2026. QTORIN™ rapamycin is also being developed for cli...
11-11 12:30
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) awarded 51,000 restricted stock units to six new employees under its 2022 Inducement Plan. The awards, granted on November 3, 2025, vest over four years, with 25% vesting annually. The company provided the information in compliance with Nasdaq Listing Rule 5635(c)(4). Arcutis focuses on创新 in免疫皮肤病学, with a portfolio of approved treatments for inflammatory skin diseases.</p>
11-07 21:00
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
美股牛股 | CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%
CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%，公司获英伟达10亿美元股权投资；阿吉赛斯大涨22%，财报表现强劲并上调收入指引>>
10-29 16:52
快讯 | Arcutis生物治疗公司：Jefferies将目标价从23美元上调至31美元
Arcutis Biotherapeutics Inc : Jefferies Raises Target Price to $31 From $23
10-29 12:21
